




**Weill Cornell
Medicine**



WangLab
Health Data Analytics
 **Weill Cornell Medicine**

Predictive Modeling with Longitudinal Patient Clinical Records

Fei Wang

Associate Professor

Department of Population Health Sciences

Weill Cornell Medicine

feiwang.cornell@gmail.com

 @feiwang03




<https://wcm-wanglab.github.io/index.html>

Disclosures



- I am consulting for the following companies
 - IBM
 - Boehringer Ingelheim
 - American Air Liquide
- Funding acknowledgement at the end

Machine Learning



<https://www.potentiaco.com/what-is-machine-learning-definition-types-applications-and-examples/>

Deep Learning



Deep Learning



<https://qbi.uq.edu.au/blog/2017/10/google-alphago-zero-masters-game-three-days>



<https://electrek.co/2017/04/29/elon-musk-tesla-plan-level-5-full-autonomous-driving/>



<https://www.shellypalmer.com/2017/01/5-awesome-illegal-uses-alexa/>



<https://siliconangle.com/2020/07/19/openais-latest-ai-text-generator-gpt-3-amazes-early-adopters/>

Medicine



The NEW ENGLAND JOURNAL of MEDICINE

Perspective

A New Initiative on Precision Medicine

Francis S. Collins, M.D., Ph.D., and Harold Varmus, M.D.
N Engl J Med 2015; 372:793-795 | February 26, 2015 | DOI: 10.1056/NEJMp1500523

Comments open through March 4, 2015

Share: [f](#) [t](#) [+](#) [in](#) [+](#)

[Article](#) [References](#) [Citing Articles \(784\)](#) [Comments \(7\)](#) [Metrics](#)

"Tonight, I'm launching a new Precision Medicine Initiative to bring us closer to curing diseases like cancer and diabetes — and to give all of us access to the personalized information we need to keep ourselves and our families healthier."

— President Barack Obama, State of the Union Address, January 20, 2015

President Obama has long expressed a strong conviction that science offers great potential for improving health. Now, the President has announced a research initiative that aims to accelerate progress toward a new era of precision medicine (www.whitehouse.gov/precisionmedicine). We believe that the time is right for this visionary initiative, and the National Institutes of Health (NIH) and other partners will work to achieve this vision.

AUDIO INTERVIEW



Interview with Dr. Francis Collins on what to expect from the recently announced Precision Medicine Initiative. (10:07)

[Listen](#)

[Download](#)

"The initiative will encourage and support the next generation of scientists to develop creative new approaches for detecting, measuring, and analyzing a wide range of biomedical information — including molecular, genomic, cellular, clinical, behavioral, physiological, and environmental parameters"

The Journey

Risk Prediction

- **Goal:**

- Build a model for predicting HF onset x months before the HF diagnosis

- **Data: Longitudinal patient records**


- Structured data:

- Demographics, Outpatient diagnoses, Problem List, Vitals, Medication, Labs

- Unstructured text: encounter notes

- **Challenge faced by our clinical partners:**

- How to systematically collect and evaluate many weak and non-specific indicators and identify the ones that combined are truly predictive



- Incorporating knowledge driven risk factors
- Accurate prediction
- Minimal redundancy:
 - Little correlation between the selected data driven risk factors and existing knowledge driven risk factor
 - Little correlation among the additional risk factors from data, to further ensure quality of the additional factors

$$f(\alpha) = \underbrace{\mathcal{L}(\mathbf{y}, \mathbf{X}\alpha)}_{\text{Model Accuracy}} + \frac{\beta}{4} \left[\underbrace{\sum_{ij \in \mathcal{D}} (\alpha_i \mathbf{x}_i^T \mathbf{x}_j \alpha_j)^2}_{\text{Correlation between data-driven features}} + \underbrace{\sum_{i \in \mathcal{D}, j \in \mathcal{K}} (\alpha_i \mathbf{x}_i^T \mathbf{x}_j \alpha_j)^2}_{\text{Correlation between data- and knowledge-driven features}} \right] + \lambda \underbrace{\|\alpha\|_1}_{\text{Sparsity Penalty}}$$

Category
Diagnosis
Medication
Lab
Symptom

Feature	Relevancy to HF
Dyslipidemia	✓
Thiazides-like Diuretics	✓
Antihypertensive Combinations	✓
Aminopenicillins	✓
Bone density regulators	✗
Natrietic Peptide	✓
Rales	✓
Diuretic Combinations	✓
S3Gallop	✓
NSAIDS	✓

Sun, Jimeng, Jianying Hu, Dijun Luo, Marianthi Markatou, **Fei Wang**, Shahram Edabollahi, Steven E. Steinhubl, Zahra Daar, and Walter F. Stewart. "Combining knowledge and data driven insights for identifying risk factors using electronic health records." In *AMIA Annual Symposium Proceedings*, vol. 2012, p. 901. American Medical Informatics Association, 2012.

Proceedings of the 2012 SIAM International Conference on Data Mining

< Previous Chapter

Table of Contents

Next Chapter >

Abstract | PDF

SOR: Scalable Orthogonal Regression for Non-Redundant Feature Selection and its Healthcare Applications

Dijun Luo, Fei Wang, Jimeng Sun, Marianthi Markatou, Jianying Hu and Shahram Ebadollahi

Abstract

As more clinical information with increasing diversity become available for analysis, a large number of features can be constructed and leveraged for predictive modeling. Feature selection is a classic analytic component that faces new challenges due to the new

This Paper Appears in

2012 SIAM
International Conference
on DATA MINING

> AMIA Annu Symp Proc. 2012;2012:901-10. Epub 2012 Nov 3.

Combining knowledge and data driven insights for identifying risk factors using electronic health records

Jimeng Sun¹, Jianying Hu, Dijun Luo, Marianthi Markatou, Fei Wang, Shahram Ebadollahi, Steven E Steinhubl, Zahra Daar, Walter F Stewart

Affiliations + expand

PMID: 23304365 PMCID: PMC3540578

Free PMC article

Low Bone Mineral Density Predicts Incident Heart Failure in Men and Women

CME

The EPIC (European Prospective Investigation Into Cancer and Nutrition)-Norfolk Prospective Study

Roman Pfister, MD,* Guido Michels, MD,* Stephen J. Sharp, MSc,† Robert Luben, BSc,‡ Nick J. Wareham, MBBS, PhD,† Kay-Tee Khaw, MBChir, PhD‡

AMJ AME MEDICAL JOURNAL
AN OPEN ACCESS GENERAL MEDICAL JOURNAL

Home Journal Info For Authors For Reviewers Special Contents All Articles Archives News

Home / March 2018 / Cardiovascular disease and bone loss—new research in identifying common disease pathophysiologies and predictors

Editorial

Check for updates

Cardiovascular disease and bone loss—new research in identifying common disease pathophysiologies and predictors

Sarah L. West¹, Emma O'Donnell²

JAHA

Journal of the American Heart Association

AHA Journals Journal Information All Issues Subjects Features Resources

Home > Journal of the American Heart Association > Vol. 6, No. 3 > Bone Mineral Density and Risk of Heart Failure in ...

OPEN ACCESS
ARTICLE

Download PDF

Bone Mineral Density and Risk of Heart Failure in Older Adults: The Cardiovascular Health Study

Raymond B. Foftung, David L. Brown, William J. H. Koh, Traci M. Bartz, Laura D. Carbone, Roberto Civitelli, Phyllis K. Stein, Paulo H. M. Chaves, Bryan R. Kestenbaum, and Jorge R. Kizer

Tools Share




Originally published 13 Mar 2017 | <https://doi.org/10.1161/JAHA.116.004344> | Journal of the American Heart Association. ;6:e004344

Matrix Representation

Definition (One-Side Convolution). The one-side convolution of $\mathbf{F} \in \mathbb{R}^{n \times m}$ and $\mathbf{g} \in \mathbb{R}^{t \times 1}$ is an $n \times t$ matrix with

$$(\mathbf{F} * \mathbf{g})_{ij} = \sum_{k=1}^t g_{j-k+1} F_{ik}$$


Note that $g_j = 0$ if $j \leq 0$ or $j > t$, and $F_{ik} = 0$ if $k > m$.



$$\begin{aligned}
 & \min_{\mathbf{F}, \mathbf{g}} \mathcal{J} \\
 & s.t. \quad \forall r = 1, \dots, R; c = 1, \dots, C \\
 & \quad \mathbf{F}^{(r)} \geq 0, \mathbf{g}_c^{(r)} \geq 0
 \end{aligned}$$

$$\mathcal{J} = \sum_{c=1}^C d_{\beta} \left(\mathbf{A}_c \odot \mathbf{X}_c, \mathbf{A}_c \odot \left(\sum_{r=1}^R \mathbf{F}^{(r)} * \mathbf{g}_c^{(r)} \right) \right) + \lambda_1 \sum_{r=1}^R \|\mathbf{F}^{(r)}\|_1 + \lambda_2 \sum_{c=1}^C \sum_{r=1}^R \|\mathbf{g}_c^{(r)}\|_1$$

Wang, Fei, Noah Lee, Jianying Hu, Jimeng Sun, and Shahram Ebadollahi. "Towards heterogeneous temporal clinical event pattern discovery: a convolutional approach." In *Proceedings of the 18th ACM SIGKDD international conference on Knowledge discovery and data mining*, pp. 453-461. 2012.




EHR of a pool of diabetic patients (n = 21,384)

CPT Code	G ₁ Description
11	Diagnostic Endocrine Procedures
15	Lens and Cataract Procedures
17	Destruction of Lesion of Retina and Choroid
18	Diagnostic Procedures on Eye
20	Other Intraocular Therapeutic Procedures
47	Diagnostic Cardiac Catheterization, Coronary Arteriography
54	Other Vascular Catheterization, Not Heart
70	Upper Gastrointestinal Endoscopy, Biopsy
76	Colonoscopy and Biopsy
77	Proctoscopy and Anorectal Biopsy
168	Incision and Drainage, Skin and Subcutaneous Tissue
169	Debridement of Wound, Infection or Burn
190	Contrast Arteriogram of Femoral and Lower Extremity Arteries
199	Electroencephalogram (EEG)
201	Cardiac Stress Tests
202	Electrocardiogram
214	Traction, Splints, and Other Wound Care
220	Ophthalmologic and Otolgic Diagnosis and Treatment
233	Laboratory -Chemistry and Hematology
240	Medications (Injections, Infusion and Other Forms)


LABS	G ₂ Description
	GLYCO and HEMOGLOBIN A1C/HEMOGLOBIN.TOTA
	LDL, CHOLESTEROL.IN LDL, and TOTAL LDL-C DIRECT
PCP	G ₃ Description
	General Primary Care Physician Visits
SPECIALTY	G ₄ Description
	NEPHROLOGY
	OPHTHALMOLOGY
	CARDIOLOGY
	NEUROLOGY
	PODIATRY
	ENDOCRINOLOGY
	PULMONOLOGY

- Repeated high Hemoglobin A1C value
- Repeated cardiac disease related procedure
- Repeated lab test (CPT code 233)
- Co-occurrence of high Hemoglobin A1C value and high Cholesterol




Wang, Fei, Noah Lee, Jianying Hu, Jimeng Sun, Shahram Ebadollahi, and Andrew F. Laine. "A framework for mining signatures from event sequences and its applications in healthcare data." *IEEE transactions on pattern analysis and machine intelligence* 35, no. 2 (2012): 272-285.

CNN for EHR Analysis




Cheng, Yu, **Fei Wang**, Ping Zhang, and Jianying Hu. "Risk prediction with electronic health records: A deep learning approach." In *Proceedings of the 2016 SIAM International Conference on Data Mining*, pp. 432-440. Society for Industrial and Applied Mathematics, 2016.



Zhu, Zihao, Changchang Yin, Buyue Qian, Yu Cheng, Jishang Wei, and **Fei Wang**. "Measuring patient similarities via a deep architecture with medical concept embedding." In *2016 IEEE 16th International Conference on Data Mining (ICDM)*, pp. 749-758. IEEE, 2016.

Sequence Representation




Markov Jump Process

Progression Stages

K phenotypes, each with its own Markov chain

Observations



Wang, Xiang, David Sontag, and Fei Wang. "Unsupervised learning of disease progression models." *In Proceedings of the 20th ACM SIGKDD international conference on Knowledge discovery and data mining*, pp. 85-94. 2014.



Progression Subtyping



**THE MICHAEL J. FOX FOUNDATION
FOR PARKINSON'S RESEARCH**

2016 PPMI DATA CHALLENGE

The Parkinson's Progression Markers Initiative (PPMI) has generated a comprehensive, standardized, longitudinal set of clinical, biological and imaging data unique to the Parkinson's disease (PD) field and ripe for novel and innovative exploration. In mid-2016, study sponsor The Michael J. Fox Foundation (MJFF) cast an open call to computational scientists, data scientists and neuroscientists to analyze PPMI data toward new insights into PD diagnosis and progression.

Parkinson's is highly variable, with age of onset, rate of progression, and type and severity of symptoms different across the 5 million worldwide living with the disease. Identifying models for prognosis and sub-typing would aid in subject selection for clinical studies and design of trials toward novel therapies.

PPMI data is uploaded in real time and accessible to qualified researchers. Learn more and download the data by visiting www.ppmi-info.org.

1. What factors at baseline predict clinical progression?
2. What are the sub-types of Parkinson's disease?

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO AND WEILL CORNELL MEDICINE RESEARCHERS NAMED WINNERS OF 2016 PARKINSON'S PROGRESSION MARKERS INITIATIVE DATA CHALLENGE





November 29, 2016

The Michael J. Fox Foundation Hosted the Challenge toward Computational Analysis of the Robust Study Dataset

Answering Fundamental Questions on Parkinson's Progression and Subtypes Will Assist in Development and Testing of New Therapies


Each Winner Receives a \$25,000 Award

NEW YORK and SAN FRANCISCO – The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces Duygu Tosun-Turgut, PhD, assistant professor of radiology and biomedical imaging at UC San Francisco and co-director of the Center for Imaging of Neurodegenerative Diseases at the San Francisco Veterans Affairs Health Care System; and Fei Wang, PhD, assistant professor of health care policy and research at Weill Cornell Medicine as winners of the MJFF-led 2016 Parkinson's Progression Markers Initiative (PPMI) Data Challenge. Each will receive a \$25,000 award furnished by MJFF and supported in part by GE Healthcare.



Subtype II (107 patients, avg age 61.93)

Moderate Baseline, Mild Progression: The patients in this subtype start with a moderate status on both their motor and non-motor capabilities at baseline (i.e., more severe than Subtype I). Both their motor and non-motor functionalities progress slowly over time.





Subtype I (201 patients, avg age 58.79)

Mild Baseline, Moderate Motor Progression: The patients in this subtype start with a mild status on both their motor and non-motor capabilities at baseline. However, their motor functionalities will decay at a moderate rate over time while their cognitive abilities are relatively stable.


Subtype III (158 patients, avg age 65.32)

Severe Baseline, Rapid Progression: The patients in this subtype start with a severe status on both their motor and non-motor capabilities at baseline (i.e., more severe than Subtype I and II). Both their motor and non-motor functionalities progress rapidly over time.


Zhang, Xi, Jingyuan Chou, Jian Liang, Cao Xiao, Yize Zhao, Harini Sarva, Claire Henchcliffe, and **Fei Wang**. "Data-driven subtyping of Parkinson's disease using longitudinal clinical records: a cohort study." *Scientific reports* 9, no. 1 (2019): 1-12.



Ma, Tengfei, Cao Xiao, and **Fei Wang**. "Health-atm: A deep architecture for multifaceted patient health record representation and risk prediction." In *Proceedings of the 2018 SIAM International Conference on Data Mining*, pp. 261-269. Society for Industrial and Applied Mathematics, 2018.



Baytas, Inci M., Cao Xiao, Xi Zhang, **Fei Wang**, Anil K. Jain, and Jiayu Zhou. "Patient subtyping via time-aware LSTM networks." In *Proceedings of the 23rd ACM SIGKDD international conference on knowledge discovery and data mining*, pp. 65-74. 2017.



Chakraborty, Prithwish, **Fei Wang**, Jianying Hu, and Daby Sow. "Explicit-Blurred Memory Network for Analyzing Patient Electronic Health Records." *arXiv preprint arXiv:1911.06472* (2019).

The Challenges


Article | [Open Access](#) | Published: 08 May 2018

Scalable and accurate deep learning with electronic health records

Alvin Rajkomar [✉](#), Eyal Oren, [Kai Chen](#), Andrew M. Dai, Nissan Hajaj, Michaela Hardt, Peter J. Liu, Xiaobing Liu, Jake Marcus, Mimi Sun, Patrik Sundberg, Hector Yee, Kun Zhang, Yi Zhang, Gerardo Flores, Gavin E. Duggan, Jamie Irvine, Quoc Le, Kurt Litsch, Alexander Mossin, Justin Tansuwan, De Wang, James Wexler, Jimbo Wilson, Dana Ludwig, Samuel L. Volchenbom, Katherine Chou, Michael Pearson, Srinivasan Madabushi, Nigam H. Shah, Atul J. Butte, Michael D. Howell, Claire Cui, Greg S. Corrado & Jeffrey Dean [-Show fewer authors](#)

npj Digital Medicine 1, Article number: 18 (2018) | [Cite this article](#)

103k Accesses | 410 Citations | 2073 Altmetric | [Metrics](#)



[HTML] Scalable and accurate deep learning with electronic health records

A Rajkomar, E Oren, K Chen, AM Dai, N Hajaj... - NPJ Digital ..., 2018 - nature.com

Predictive modeling with electronic health record (EHR) data is anticipated to drive personalized medicine and improve healthcare quality. Constructing predictive statistical models typically requires extraction of curated predictor variables from normalized EHR ...

☆ [🔗](#) **Cited by 802** [Related articles](#) [All 16 versions](#)

<https://www.nature.com/articles/s41746-018-0029-1>

In-hospital mortality prediction

- the most recent systolic blood pressure, heart-rate, respiratory rate and temperature in Fahrenheit
- the most recent white blood cell count hemoglobin, sodium, creatinine, troponin, lactate oxygen saturation, oxygen source, glucose, calcium, potassium, chloride, blood urea nitrogen (BUN), carbon dioxide, hematocrit, platelet, magnesium, phosphorus, albumin, aspartate transaminase (AST), Alkaline Phosphatase, Total Bilirubin, International Normalized Ratio, and Absolute Neutrophil Count (ANC)

Hospital readmission prediction


Hemoglobin level at discharge, g/dL	≥12 0	<12 +1
Discharged from oncology service	No 0	Yes +2
Sodium level at discharge, mEq/L	≥135 0	<135 +1
Any ICD-9 coded procedure performed during hospital stay	No 0	Yes +1
Index admission type	Elective 0	Urgent or emergent +1
Number of hospital admissions during the previous year	0-1 0	2-5 +2 >5 +5
Length of stay	<5 days 0	≥5 days +2

Length-of-stay prediction

- prior HCC codes in the timeline (counts for each one), the principal diagnosis coded as a CCS, hospital service, and the most recent lab value of each possible lab used in the mortality baseline model.



Weighted RNN



Feedforward NN with Time-Aware Attention



Boosted Decision Stumps

	Hospital A	Hospital B
Inpatient Mortality, AUROC¹(95% CI)		
Deep learning 24 hours after admission	0.95 (0.94-0.96)	0.93 (0.92-0.94)
Full feature enhanced baseline at 24 hours after admission	0.93 (0.92-0.95)	0.91 (0.89-0.92)
Full feature simple baseline at 24 hours after admission	0.93 (0.91-0.94)	0.90 (0.88-0.92)
Baseline (aEWS ²) at 24 hours after admission	0.85 (0.81-0.89)	0.86 (0.83-0.88)
30-day Readmission, AUROC (95% CI)		
Deep learning at discharge	0.77 (0.75-0.78)	0.76 (0.75-0.77)
Full feature enhanced baseline at discharge	0.75 (0.73-0.76)	0.75 (0.74-0.76)
Full feature simple baseline at discharge	0.74 (0.73-0.76)	0.73 (0.72-0.74)
Baseline (mHOSPITAL ³) at discharge	0.70 (0.68-0.72)	0.68 (0.67-0.69)
Length of Stay at least 7 days AUROC (95% CI)		
Deep learning 24 hours after admission	0.86 (0.86-0.87)	0.85 (0.85-0.86)
Full feature enhanced baseline at 24 hours after admission	0.85 (0.84-0.85)	0.83 (0.83-0.84)
Full feature simple baseline at 24 hours after admission	0.83 (0.82-0.84)	0.81 (0.80-0.82)
Baseline (mLiu ⁴) at 24 hours after admission	0.76 (0.75-0.77)	0.74 (0.73-0.75)

¹ Area under the receiver operator curve

² Augmented early warning score

³ Modified HOSPITAL score

⁴ Modified Liu score

Article | [Open Access](#) | Published: 20 February 2019


Predictive Modeling of the Hospital Readmission Risk from Patients' Claims Data Using Machine Learning: A Case Study on COPD

Xu Min, Bin Yu & Fei Wang [✉](#)

Scientific Reports **9**, Article number: 2362 (2019) | [Cite this article](#)


9854 Accesses | **23** Citations | **17** Altmetric | [Metrics](#)

<https://www.nature.com/articles/s41598-019-39071-y>




Feature x		Dimension (one-year history)	Dimension (full history)
Knowledge-driven	HOS	4	—
	LACE	4	—
	hand	12	12
Data-driven	DX	9743	10306
	DX_3dig	1153	1169
	DX_CCS	285	285
	DX_HCC	197	197
	PROC	11193	12009
	PROC_group	399	402
	PHAR	20289	22964
	PHAR_GTC	42	42
LC	32	33	

	LR	LR_l1	LR_l2	RF	SVM	GBDT	MLP
One year	0.617	0.616	0.617	0.636	0.612	0.653	0.571
Full history	0.635	0.644	0.645	0.624	0.643	0.654	0.627



(a) Different time fusion methods.



(b) Different embedding strategies.

Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality

RECEIVED 15 January 2014
 REVISED 10 June 2014
 ACCEPTED 3 July 2014
 PUBLISHED ONLINE FIRST 22 July 2014



Hua Xu¹, Melinda C Aldrich^{2,3}, Qingxia Chen^{4,5}, Hongfang Liu⁶, Neeraja B Peterson⁷, Qi Dai³, Mia Levy^{5,7}, Anushi Shah⁵, Xue Han⁴, Xiaoyang Ruan⁶, Min Jiang¹, Ying Li⁸, Jamii St Julien², Jeremy Warner^{5,7}, Carol Friedman⁸, Dan M Roden^{7,9}, Joshua C Denny^{5,7}

Figure 3: Kaplan–Meier (K–M) plot of overall cancer survival for the Vanderbilt and Mayo Clinic cohorts. DM2, type 2 diabetes mellitus.




Figure 1: The study design and data extraction workflow for patients in the Vanderbilt electronic health record (EHR) system from January 1995 to December 2010.





Figure 2: The study design and data extraction workflow for patients in the Mayo Clinic electronic health record (EHR) system from January 1995 to December 2010.



Extended “Big Data” Analysis

- Single Drug



153 drugs for chronic diseases



- Carefully selected covariates (30+)

Site	PRODUCT	Prod	Month	Year	Units Sold	Revenue
1	Sildenafil	Handout	March	2000	1000	\$20,000.00
2	Sildenafil	Handout	February	2000	1000	\$20,000.00
3	Sildenafil	Handout	January	2000	1000	\$20,000.00
4	Sildenafil	Handout	December	1999	1000	\$20,000.00
5	Sildenafil	Handout	November	1999	1000	\$20,000.00
6	Sildenafil	Handout	October	1999	1000	\$20,000.00
7	Sildenafil	Handout	September	1999	1000	\$20,000.00
8	Sildenafil	Handout	August	1999	1000	\$20,000.00
9	Sildenafil	Handout	July	1999	1000	\$20,000.00
10	Sildenafil	Handout	June	1999	1000	\$20,000.00
11	Sildenafil	Handout	May	1999	1000	\$20,000.00
12	Sildenafil	Handout	April	1999	1000	\$20,000.00
13	Sildenafil	Handout	March	1999	1000	\$20,000.00
14	Sildenafil	Handout	February	1999	1000	\$20,000.00
15	Sildenafil	Handout	January	1999	1000	\$20,000.00



all-inclusive covariates (3000+)

Site	PRODUCT	Prod	Month	Year	Units Sold	Revenue	Site	PRODUCT	Prod	Month	Year	Units Sold	Revenue
1	Sildenafil	Handout	March	2000	1000	\$20,000.00	16	Sildenafil	Handout	March	2000	1000	\$20,000.00
2	Sildenafil	Handout	February	2000	1000	\$20,000.00	17	Sildenafil	Handout	February	2000	1000	\$20,000.00
3	Sildenafil	Handout	January	2000	1000	\$20,000.00	18	Sildenafil	Handout	January	2000	1000	\$20,000.00
4	Sildenafil	Handout	December	1999	1000	\$20,000.00	19	Sildenafil	Handout	December	1999	1000	\$20,000.00
5	Sildenafil	Handout	November	1999	1000	\$20,000.00	20	Sildenafil	Handout	November	1999	1000	\$20,000.00
6	Sildenafil	Handout	October	1999	1000	\$20,000.00	21	Sildenafil	Handout	October	1999	1000	\$20,000.00
7	Sildenafil	Handout	September	1999	1000	\$20,000.00	22	Sildenafil	Handout	September	1999	1000	\$20,000.00
8	Sildenafil	Handout	August	1999	1000	\$20,000.00	23	Sildenafil	Handout	August	1999	1000	\$20,000.00
9	Sildenafil	Handout	July	1999	1000	\$20,000.00	24	Sildenafil	Handout	July	1999	1000	\$20,000.00
10	Sildenafil	Handout	June	1999	1000	\$20,000.00	25	Sildenafil	Handout	June	1999	1000	\$20,000.00
11	Sildenafil	Handout	May	1999	1000	\$20,000.00	26	Sildenafil	Handout	May	1999	1000	\$20,000.00
12	Sildenafil	Handout	April	1999	1000	\$20,000.00	27	Sildenafil	Handout	April	1999	1000	\$20,000.00
13	Sildenafil	Handout	March	1999	1000	\$20,000.00	28	Sildenafil	Handout	March	1999	1000	\$20,000.00
14	Sildenafil	Handout	February	1999	1000	\$20,000.00	29	Sildenafil	Handout	February	1999	1000	\$20,000.00
15	Sildenafil	Handout	January	1999	1000	\$20,000.00	30	Sildenafil	Handout	January	1999	1000	\$20,000.00

- Hypothesis Driven



Data Driven

Rank	Drug	HR	P-value	Lower	Upper	Adj-p-value
1	sildenafil	0.704	0.000	0.621	0.797	0.000
2	olmesartan	0.714	0.001	0.580	0.879	0.017
3	thyroxine	0.791	0.000	0.734	0.852	0.000
4	carvedilol	0.803	0.003	0.693	0.930	0.033
5	alendronic.acid	0.812	0.000	0.725	0.908	0.004
6	amlodipine	0.839	0.000	0.782	0.901	0.000
7	epoetin.alfa.recom	0.840	0.000	0.772	0.914	0.001
8	ramipril	0.843	0.004	0.750	0.947	0.036
9	simvastatin	0.845	0.000	0.788	0.906	0.000
10	atorvastatin	0.861	0.000	0.797	0.930	0.003
11	metformin	0.862	0.003	0.781	0.952	0.033
12	esomeprazole	0.878	0.000	0.819	0.942	0.004
13	omeprazole	0.879	0.000	0.830	0.931	0.000
14	lisinopril	0.902	0.002	0.846	0.962	0.018
15	lansoprazole	0.908	0.005	0.849	0.971	0.037

Pneumonia & Asthma

A rule based machine learning algorithm suggested considering patients with both pneumonia and asthma to be at a lower risk of death from pneumonia than patients with pneumonia but without asthma

At the hospitals hosting this study, patients with a history of asthma who presented with pneumonia were usually admitted directly to intensive care units to prevent complications, this led to patients with pneumonia and asthma having better outcomes than patients diagnosed with pneumonia and without the history of asthma, with an approximately 50% mortality risk reduction (5.4% vs. 11.3%)

Caruana, Rich, Yin Lou, Johannes Gehrke, Paul Koch, Marc Sturm, and Noemie Elhadad. "Intelligible models for healthcare: Predicting pneumonia risk and hospital 30-day readmission." In *Proceedings of the 21th ACM SIGKDD international conference on knowledge discovery and data mining*, pp. 1721-1730. 2015.

Common Symptoms



fever, sweating, and/or chills



severe cough



shortness of breath and/or difficulty breathing



chest pain when coughing or breathing



loss of appetite




nausea, diarrhea, or vomiting



fatigue



feeling weak



ORIGINAL ARTICLE

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

The REMAP-CAP Investigators*

RESULTS

Both tocilizumab and sarilumab met the predefined criteria for efficacy. At that time, 353 patients had been assigned to tocilizumab, 48 to sarilumab, and 402 to control. The median number of organ support–free days was 10 (interquartile range, –1 to 16) in the tocilizumab group, 11 (interquartile range, 0 to 16) in the sarilumab group, and 0 (interquartile range, –1 to 15) in the control group. The median adjusted cumulative odds ratios were 1.64 (95% credible interval, 1.25 to 2.14) for tocilizumab and 1.76 (95% credible interval, 1.17 to 2.91) for sarilumab as compared with control, yielding posterior probabilities of superiority to control of more than 99.9% and of 99.5%, respectively. An analysis of 90-day survival showed improved survival in the pooled interleukin-6 receptor antagonist groups, yielding a hazard ratio for the comparison with the control group of 1.61 (95% credible interval, 1.25 to 2.08) and a posterior probability of superiority of more than 99.9%. All secondary analyses supported efficacy of these interleukin-6 receptor antagonists.

CONCLUSIONS

In critically ill patients with Covid-19 receiving organ support in ICUs, treatment with the interleukin-6 receptor antagonists tocilizumab and sarilumab improved outcomes, including survival. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.)

ORIGINAL ARTICLE

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I.O. Rosas, N. Bräu, M. Waters, R.C. Go, B.D. Hunter, S. Bhagani, D. Skiect, M.S. Aziz, N. Cooper, I.S. Douglas, S. Savic, T. Youngstein, L. Del Sorbo, A. Cubillo Gracian, D.J. De La Zerda, A. Ustianowski, M. Bao, S. Dimonaco, E. Graham, B. Matharu, H. Spotswood, L. Tsai, and A. Malhotra

RESULTS

Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, –1.0; 95% CI, –2.5 to 0; $P=0.31$ by the van Elteren test). In the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points (95% CI, –7.6 to 8.2; nominal $P=0.94$).

CONCLUSIONS

In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann–La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615.)

The Future

Understand the Data

thebmj

Research ▾ Education ▾ News & Views ▾ Campaigns ▾ Jobs ▾

Research

Biases in electronic health record data due to processes within the healthcare system: retrospective observational study

BMJ 2018 ; 361 doi: <https://doi.org/10.1136/bmj.k1479> (Published 30 April 2018)

Cite this as: BMJ 2018;361:k1479

Denis Agniel, research fellow¹, Isaac S Kohane, department head^{1 2}, Griffin M Weber, associate professor^{1 3}

Author affiliations ▾

¹Department of Biomedical Informatics, Harvard Medical School, 10 Shattuck St,





Boston, MA 02115, USA

²Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA


³Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

Correspondence to: G M Weber weber@hms.harvard.edu

<https://www.bmj.com/content/361/bmj.k1479>



Knowledge is Important



CLASSIFYING CLINICALLY ACTIONABLE GENETIC MUTATIONS


NIPS 2017 COMPETITION

Once sequenced, a cancer tumor can have thousands of **genetic mutations**. But the challenge is distinguishing the mutations that contribute to tumor growth (drivers) from the neutral mutations (passengers).

Currently this interpretation of genetic mutations is being done **manually**. This is a very time-consuming task where a clinical pathologist has to manually review and classify every single genetic mutation based on evidence from **text-based clinical literature**.

For this competition MSKCC is making available an expert-annotated knowledge base where world-class researchers and oncologists have **manually** annotated thousands of mutations.

The goal of this competition is to develop a Machine Learning algorithm that, using this knowledge base as a baseline, **automatically** classifies genetic variations.



<https://www.mskcc.org/news/msk-advances-its-ai-machine-learning-nips-2017>

Zhang, Xi, Dandi Chen, Yongjun Zhu, Chao Che, Chang Su, Sendong Zhao, Xu Min, and Fei Wang. "Multi-view ensemble classification for clinically actionable genetic mutations." In *The NIPS'17 Competition: Building Intelligent Systems*, pp. 79-99. Springer, Cham, 2018.

Model Underspecification

Underspecification Presents Challenges for Credibility in
Modern Machine Learning

Alexander D'Amour*
Katherine Heller*
Dan Moldovan*
Ben Adlam
Babak Alipanahi
Alex Beutel
Christina Chen
Jonathan Deaton
Jacob Eisenstein
Matthew D. Hoffman
Farhad Hormozdiari
Neil Houlsby
Shaobo Hou
Ghassen Jerfel
Alan Karthikesalingam
Mario Lucic
Yian Ma
Cory McLean
Diana Mincu
Akinori Mitani
Andrea Montanari
Zachary Nado
Vivek Natarajan
Christopher Nielson†
Thomas F. Osborne†
Rajiv Raman
Kim Ramasamy
Rory Sayres
Jessica Schrouff
Martin Seneviratne
Shannon Sequeira
Harini Suresh
Victor Veitch
Max Vladymyrov
Xuezhi Wang
Kellie Webster
Steve Yadlowsky
Taedong Yun
Xiaohua Zhai
D. Sculley

ALEXDAMOUR@GOOGLE.COM
KHELLER@GOOGLE.COM
MDAN@GOOGLE.COM
ADLAM@GOOGLE.COM
BABAKA@GOOGLE.COM
ALEXBEUTEL@GOOGLE.COM
CHRISTINIUM@GOOGLE.COM
JDEATON@GOOGLE.COM
JEISENSTEIN@GOOGLE.COM
MHOFFMAN@GOOGLE.COM
FHORMOZ@GOOGLE.COM
NEILHOULSBY@GOOGLE.COM
SHAOBOHOU@GOOGLE.COM
GHASSEN@GOOGLE.COM
ALANKARTHI@GOOGLE.COM
LUCIC@GOOGLE.COM
YIANMA@UCSD.EDU
CYM@GOOGLE.COM
DMINCU@GOOGLE.COM
AMITANI@GOOGLE.COM
MONTANARI@STANFORD.EDU
ZNADO@GOOGLE.COM
NATVIV@GOOGLE.COM
CHRISTOPHER.NIELSON@VA.GOV
THOMAS.OSBORNE@VA.GOV
DRRRN@SNMAIL.ORG
KIM@ARAVIND.ORG
SAYRES@GOOGLE.COM
SCHROUFF@GOOGLE.COM
MARTSEN@GOOGLE.COM
SHNNN@GOOGLE.COM
HSURESH@MIT.EDU
VICTORVEITCH@GOOGLE.COM
MXV@GOOGLE.COM
XUEZHIW@GOOGLE.COM
WEBSTERK@GOOGLE.COM
YADLOWSKY@GOOGLE.COM
TEDYUN@GOOGLE.COM
XZHAI@GOOGLE.COM
DSCULLEY@GOOGLE.COM

MIT Technology Review


Artificial intelligence / Machine learning

The way we train AI is fundamentally flawed

The process used to build most of the machine-learning models we use today can't tell if they will work in the real world or not—and that's a problem.

by Will Douglas Heaven

November 18, 2020




<https://www.technologyreview.com/2020/11/18/1012234/training-machine-learning-broken-real-world-health-nlp-computer-vision/>



ARTIFICIAL NEURAL NETWORKS

Google Researchers Discover Underspecification Problem Holding Back Many AI Models

Published 1 week ago on November 20, 2020
By Daniel Nelson




<https://www.unite.ai/google-researchers-discover-underspecification-problem-holding-back-many-ai-models/>



arXiv:2011.03395v2 [cs.LG] 24 Nov 2020

the solution to a problem is underspecified if
there are many distinct solutions that solve
the problem equivalently

Transfer Learning




TRANSFER LEARNING




Keremany, Daniel S., Michael Goldbaum, Wenjia Cai, Carolina CS Valentim, Huiying Liang, Sally L. Baxter, Alex McKeown et al. "Identifying medical diagnoses and treatable diseases by image-based deep learning." *Cell* 172, no. 5 (2018): 1122-1131.

Zhang, Xi Sheryl, Fengyi Tang, Hiroko H. Dodge, Jiayu Zhou, and **Fei Wang**. "Metapred: Meta-learning for clinical risk prediction with limited patient electronic health records." In *Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining*, pp. 2487-2495. 2019.

Federated Learning




Federated Learning




Vaid, Akhil, Suraj K. Jaladanki, Jie Xu, Shelly Teng, Arvind Kumar, Samuel Lee, Sulaiman Somani, Jessica K De Freitas, Tingyi Wanyan, Kipp W Johnson, Mesude Bicak, Eyal Klang, Young Joon Kwon, Anthony Costa, Shan Zhao, Riccardo Miotto, Alexander W Charney, Erwin Böttinger, Zahi A Fayad, Girish N Nadkarni, **Fei Wang**, Benjamin S Glicksberg. "Federated learning of electronic health records improves mortality prediction in patients hospitalized with covid-19." *JMIR Medical Informatics* (2021).

Multi-Modal Learning



Multi-Modal Learning



Model Interpretation

Annals of Internal Medicine®


LATEST ISSUES CHANNELS CME/MOC IN THE CLINIC JOURNAL CLUB WEB EXCLUSIVES AUTHOR INFO

[PREV ARTICLE](#) | [THIS ISSUE](#) | [NEXT ARTICLE](#)


IDEAS AND OPINIONS | 7 JANUARY 2020

Should Health Care Demand Interpretable Artificial Intelligence or Accept “Black Box” Medicine?

Fei Wang, PhD; Rainu Kaushal, MD, MPH; Dhruv Khullar, MD, MPP



Intrinsic Interpretability



Post-hoc Interpretability

Attention Is All You Need

Ashish Vaswani*
Google Brain
avaswani@google.com

Noam Shazeer*
Google Brain
noam@google.com

Niki Parmar*
Google Research
nikip@google.com

Jakob Uszkoreit*
Google Research
usz@google.com

Llion Jones*
Google Research
llion@google.com

Aidan N. Gomez* †
University of Toronto
aidan@cs.toronto.edu

Lukasz Kaiser*
Google Brain
lukaszkaizer@google.com

Illia Polosukhin* ‡
illia.polosukhin@gmail.com

Abstract

The dominant sequence transduction models are based on complex recurrent or convolutional neural networks that include an encoder and a decoder. The best performing models also connect the encoder and decoder through an attention mechanism. We propose a new simple network architecture, the Transformer, based solely on attention mechanisms, dispensing with recurrence and convolutions entirely. Experiments on two machine translation tasks show these models to be superior in quality while being more parallelizable and requiring significantly less time to train. Our model achieves 28.4 BLEU on the WMT 2014 English-to-German translation task, improving over the existing best results, including ensembles, by over 2 BLEU. On the WMT 2014 English-to-French translation task, our model establishes a new single-model state-of-the-art BLEU score of 41.8 after training for 3.5 days on eight GPUs, a small fraction of the training costs of the best models from the literature. We show that the Transformer generalizes well to other tasks by applying it successfully to English constituency parsing both with large and limited training data.

Attention is not Explanation

Sarthak Jain
Northeastern University
jain.sar@husky.neu.edu

Byron C. Wallace
Northeastern University
b.wallace@northeastern.edu

Attention is not not Explanation

Sarah Wiegrefe*
School of Interactive Computing
Georgia Institute of Technology
saw@gatech.edu

Yuval Pinter*
School of Interactive Computing
Georgia Institute of Technology
uvp@gatech.edu

Why is Attention Not So Interpretable?


Bing Bai^{1*}, Jian Liang^{2*}, Guanhua Zhang^{1,3}, Hao Li¹, Kun Bai¹, Fei Wang⁴
¹Tencent Inc., China, ²Alibaba Inc., China,
³Harbin Institute of Technology, China, ⁴Cornell University, USA
{icebai, guanzhang, leehaoli, kunbai}@tencent.com,
xuelang.lj@alibaba-inc.com, few2001@med.cornell.edu

Routine Laboratory Blood Tests Predict SARS-CoV-2 Infection Using Machine Learning FREE

He S Yang ✉, Yu Hou, Ljiljana V Vasovic, Peter A D Steel, Amy Chadburn, Sabrina E Racine-Brzostek, Priya Velu, Melissa M Cushing, Massimo Loda, Rainu Kaushal
 ... Show more
 Author Notes

Clinical Chemistry, Volume 66, Issue 11, November 2020, Pages 1396–1404,
<https://doi.org/10.1093/clinchem/hvaa200>

Published: 30 October 2020 Article history ▼



Approximation Trees: Statistical Stability in Model Distillation

Yichen Zhou, Zhengze Zhou, Giles Hooker
 Department of Statistical Science
 Cornell University
 Ithaca, NY 14853, USA

Abstract

This paper examines the stability of learned explanations for black-box predictions via model distillation with decision trees. One approach to intelligibility in machine learning is to use an understandable “student” model to mimic the output of an accurate “teacher”. Here, we consider the use of regression trees as a student model, in which nodes of the tree can be used as “explanations” for particular predictions, and the whole structure of the tree can be used as a global representation of the resulting function.

However, individual trees are sensitive to the particular data sets used to train them, and an interpretation of a student model may be suspect if small changes in the training data have a large effect on it. In this context, access to outcomes from a teacher helps to stabilize the greedy splitting strategy by generating a much larger corpus of training examples than was originally available. We develop tests to ensure that enough examples are generated at each split so that the same splitting rule would be chosen with high probability were the tree to be re-trained. Further, we develop a stopping rule to indicate how deep the tree should be built based on recent results on the variability of Random Forests when these are used as the teacher. We provide concrete examples of these procedures on the CAD-MDD and COMPAS data sets.

Model Security




Adversarial machine learning is a technique employed in the field of machine learning which attempts to **fool models through malicious input**. This technique can be applied for a variety of reasons, the most common being to attack or cause a malfunction in standard machine learning models.



"panda"

57.7% confidence

+ ϵ



=



"gibbon"

99.3% confidence

<https://arxiv.org/abs/1412.6572>

Researchers Find a Malicious Way to Meddle with Autonomous Cars

MARK HARRIS AUG 4, 2017



<https://www.caranddriver.com/news/a15340148/researchers-find-a-malicious-way-to-meddle-with-autonomous-cars/>

SHARE POLICY FORUM | MACHINE LEARNING



Adversarial attacks on medical machine learning

Samuel G. Finlayson¹, John D. Bowers², Joichi Ito³, Jonathan L. Zittrain², Andrew L. Beam⁴, Isaac S. Kohane¹
 + See all authors and affiliations

Science 22 Mar 2019:
 Vol. 363, Issue 6433, pp. 1287-1289
 DOI: 10.1126/science.aaw4399

The anatomy of an adversarial attack


Demonstration of how adversarial attacks against various medical AI systems might be executed without requiring any overtly fraudulent misrepresentation of the data.

Original image



+ 0.04 ×

Adversarial noise



=


Adversarial example




Dermatoscopic image of a benign melanocytic nevus, along with the diagnostic probability computed by a deep neural network.

Perturbation computed by a common adversarial attack technique. See (7) for details.

Combined image of nevus and attack perturbation and the diagnostic probabilities from the same deep neural network.




Model Security



$$\min_{\tilde{X}} \max \left\{ \left[\text{Logit}(\tilde{X}) \right]_{y_{\theta}} - \left[\text{Logit}(\tilde{X}) \right]_{\tilde{y}_{\theta}}, -\kappa \right\} + \lambda \|\tilde{X} - X\|_1$$

Model Bias



Science

Contents ▾

News ▾

Careers ▾

Journals ▾

SHARE

RESEARCH ARTICLE



Dissecting racial bias in an algorithm used to manage the health of populations

Ziad Obermeyer^{1,2,*}, Brian Powers³, Christine Vogeli⁴, Sendhil Mullainathan^{5,*},†

+ See all authors and affiliations

Science 25 Oct 2019:
Vol. 366, Issue 6464, pp. 447-453
DOI: 10.1126/science.aax2342

xOrder: A Model Agnostic Post-Processing Framework for Achieving Ranking Fairness While Maintaining Algorithm Utility

Sen Cui^{1*} Weishen Pan^{1*} Changshui Zhang¹ Fei Wang²

Acknowledgement

- Current Members

- Chang Su
- Jie Xu
- Zhenxing Xu
- Chengxi Zang
- Yu Hou
- Hao Zhang
- Matthew Brendel

- Alumni

- Xi Zhang
- Yongjun Zhu
- Lifang He
- Sendong Zhao
- Jingyuan Chou
- Dandi Chen

- Collaborators

- Robert Aseltine (Psychiatry)
- Daniel Barone (Neurology)
- Larry Casalino (Health Policy)
- Kun Chen (Statistics)
- Hiroko Dodge (Neurology)
- Olivier Elemento (System Biology)
- James Flory (Endocrinology)
- Parag Goyal (Cardiology)
- Zachary Grinspan (Neurology)
- Claire Henchcliffe (Neurology)
- Giles Hooker (Statistics)
- Richard Isaacson (Neurology)
- Dhruv Khullar (Internal Medicine)
- Anais Rameau (Otolaryngology)
- Harini Sarva (Neurology)
- Edward Schenck (Intensivist)
- Sarina He Yang (Lab Medicine)


Acknowledgement



mitre




Boehringer
Ingelheim



FORCE CLOUDS



OCEANIX



“The greatest opportunity offered by AI is not reducing errors or workloads, or even curing cancer: it is the opportunity to restore the precious and time-honored connection and trust—the human touch—between patients and doctors”



feiwang.cornell@gmail.com

